Same drug interaction concerns as berberine (CYP3A4, P-gp, CYP2D6) but potentially amplified by higher bioavailability. Pregnancy: CONTRAINDICATED. Hypoglycaemia risk with antidiabetic drugs. See berberine entry.
Reduced form of berberine with improved GI absorption and conversion back to berberine after intestinal absorption. Lower GI side effects than berberine. Same AMPK-activating mechanism.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)